Healthcare Technology for Providers Stocks Q1 Earnings: Omnicell (NASDAQ:OMCL) Best of the Bunch
The article reviews the Q1 earnings of healthcare technology for providers stocks, highlighting Omnicell (OMCL) as the top performer. Omnicell exceeded analyst expectations with strong revenue growth and improved EBITDA guidance. Other companies like Astrana Health also reported significant revenue increases, while Evolent Health and Privia Health had mixed results.
Is It Too Late To Consider Omnicell (OMCL) After A 63% One-Year Share Price Surge?
Omnicell (OMCL) has seen a significant 63% share price surge over the past year, prompting an evaluation of its current valuation using DCF analysis and P/E ratios. While a Discounted Cash Flow model suggests the stock is 17.4% undervalued, its P/E ratio of 99.54x is considerably higher than industry averages, indicating it might be overvalued through that lens. The article encourages investors to consider different "Narratives" on Simply Wall St's platform to align their own view on Omnicell's future prospects with a Fair Value estimate.
Omnicell EVP Corey Manley sells $217,180 in OMCL shares
Corey J. Manley, EVP and Chief Legal/Administrative Officer at Omnicell (NASDAQ:OMCL), recently sold 5,025 shares for $217,180 and disposed of another 4,041 shares worth $174,247 for tax purposes on May 18 and May 15, 2026, respectively. These transactions occurred as Omnicell's shares are trading higher and the company reported strong first-quarter 2026 earnings, leading to positive analyst sentiment and raised price targets from Piper Sandler and KeyBanc.
Omnicell EVP Corey Manley sells $217,180 in OMCL shares
Corey J. Manley, EVP and Chief Legal/Administrative Officer at Omnicell (NASDAQ:OMCL), recently sold 5,025 shares of OMCL stock worth $217,180 and disposed of an additional 4,041 shares valued at $174,247 for tax purposes. These transactions occurred on May 18, 2026, and May 15, 2026, respectively, leaving Manley with 112,783.3392 shares. The sales come amidst positive financial news for Omnicell, including strong Q1 2026 earnings and increased price targets from analysts, although the stock trades at a high P/E ratio.
Omnicell (OMCL) CEO uses 12,347 shares to cover RSU tax withholding
Omnicell Inc.'s CEO, Randall A. Lipps, reported a tax-related share disposition where 12,347 shares of common stock were withheld to cover taxes due to the vesting of restricted stock units. The shares were withheld at a price of $43.12 per share on May 15, 2026. After this transaction, Mr. Lipps directly holds approximately 523,184 shares, with additional indirect holdings in trusts for his wife and children.
Omnicell (OMCL) COO reports 3,090-share sale and RSU tax withholding
Omnicell's EVP and COO, Nnamdi Njoku, reported the open-market sale of 3,090 shares of common stock at $43.22 per share under a pre-arranged Rule 10b5-1 trading plan. Additionally, 3,660 shares were withheld to cover taxes associated with the vesting of restricted stock units. After these transactions, Njoku directly holds approximately 154,785 shares in the company.
Omnicell (OMCL) officer has 226 shares withheld to cover RSU taxes
Omnicell, Inc.'s VP and Chief Accounting Officer, Brian H. Nutt, had 226 shares of common stock withheld to cover taxes due upon the vesting of restricted stock units. This tax-related disposition, valued at $43.12 per share, was not an open-market transaction. Following this, Nutt directly holds 22,859.6135 shares of Omnicell common stock.
Is Analyst Optimism And Wellington’s Stake Reshaping The Investment Case For Omnicell (OMCL)?
Following robust fiscal Q1 2026 results and a newly disclosed 5.96% stake by Wellington Management, analysts have updated their views on Omnicell (OMCL), highlighting its product innovation and market positioning. The company's investment narrative centers on transitioning to higher-margin, recurring software revenue through its OmniSphere platform. Investors are now focused on Omnicell's ability to convert its product breadth into predictable revenue streams amidst competitive pressures and potential buyer consolidation.
Is Analyst Optimism And Wellington’s Stake Reshaping The Investment Case For Omnicell (OMCL)?
Omnicell (OMCL) is drawing investor attention due to analyst reactions to its Q1 2026 results, highlighting demand and product innovation, coupled with Wellington Management disclosing a significant stake. The investment case hinges on Omnicell's ability to transition to higher-margin, recurring software-driven revenue through its automated medication management and OmniSphere platform. While analyst optimism and institutional interest are noted, potential risks include pricing pressure from buyer consolidation and hospital budget constraints.
Is Analyst Optimism And Wellington’s Stake Reshaping The Investment Case For Omnicell (OMCL)?
Omnicell (OMCL) is gaining investor attention following positive Q1 2026 results and a disclosed 5.96% stake by Wellington Management. Analysts have highlighted the company's product innovation in medication management and the OmniSphere platform, expecting a shift towards higher recurring, software-driven revenue and improved margins. However, the article also cautions investors to consider potential risks like buyer consolidation and pricing pressure despite the renewed optimism and institutional interest.
OMCL (NASDAQ) director files to sell 5,025 vested shares via Fidelity
OMNICELL, INC. (OMCL) has submitted a Form 144 notice disclosing a proposed sale of 5,025 shares of common stock. These shares are tied to restricted stock vesting on May 15, 2026, and the transaction is being handled by Fidelity Brokerage Services LLC. The filing also notes a previous sale of 7,405 shares on March 16, 2026, for $256,879.45.
OMNICELL, INC. SEC Filing
This article provides details of a Form 144 SEC filing by Omnicell, Inc. concerning a proposed sale of securities. The filing indicates a sale of 3,090 shares of common stock with an aggregate market value of $133,549.80, acquired through restricted stock vesting. The notice was dated May 18, 2026, with the approximate sale date also May 18, 2026.
Dana Investment Advisors Inc. Purchases New Shares in Omnicell, Inc. $OMCL
Dana Investment Advisors Inc. acquired a new stake in Omnicell, Inc. (NASDAQ:OMCL) by purchasing 76,057 shares valued at approximately $3.45 million during the fourth quarter, establishing a 0.17% ownership. Omnicell reported strong Q1 results, with EPS of $0.55 and revenue of $309.88 million exceeding expectations, and a 14.9% year-over-year sales increase. Analyst sentiment is positive, with several firms raising ratings and price targets, resulting in an average "Buy" rating and a target price around $59.86 for OMCL.
Omnicell Inc stock (US6821321088): pharmacy automation specialist after latest earnings update
Omnicell Inc, a US-based provider of medication management and pharmacy automation solutions, recently updated investors on its quarterly results, cost-saving plans, and outlook for 2025. The company specializes in automating and digitizing medication processes in healthcare settings, aiming to reduce errors and improve efficiency. Its strategy includes increasing recurring revenue from software and services to provide more predictable cash flows and deepen customer relationships.
Omnicell Stock Analysis: Is It a Buy or a Portfolio Risk After 23% Gain? - News and Statistics
Omnicell (OMCL) has seen a 23% return in the past six months, outperforming the S&P 500, but analysts warn of potential downside risks. Despite revenue growth, earnings per share have declined, and the company's return on invested capital is low. The stock's current valuation at 23.2 times forward price-to-earnings is considered optimistic, leading experts to suggest better fundamental alternatives.
Omnicell (OMCL) is a great momentum stock: Should you buy?
This article evaluates Omnicell (OMCL) as a potential momentum stock investment. It suggests that momentum investors might find OMCL appealing due to its recent performance, signaling if it could be a suitable addition to a portfolio.
Wellington affiliates hold 5.96% of Omnicell (OMCL) common stock
Multiple Wellington entities have collectively reported beneficial ownership of 2,707,046 shares of Omnicell (OMCL) common stock, which represents 5.96% of the class as of March 31, 2026. This disclosure was made via a Schedule 13G filing, indicating a passive investment. The filing specifies shared voting power of 1,808,062 shares and shared dispositive power of 2,707,046 shares among the reporting entities.
Omnicell's (NASDAQ:OMCL) Conservative Accounting Might Explain Soft Earnings
Omnicell's recent earnings report, despite showing soft profit numbers, was met positively by the market due to underlying factors. The company's statutory profit was reduced by US$6.5m due to unusual items, which are often one-off and suggest an underestimation of its true earnings potential. If these unusual expenses do not recur, Omnicell's profit is expected to increase in the coming year.
Here is What Analysts Are Saying About Omnicell, Inc. (OMCL)
Following its strong Q1 2026 financial results, analysts have updated their ratings and price targets for Omnicell, Inc. (OMCL). Craig-Hallum reiterated a Buy rating and raised its price target to $55, citing strong demand and innovation, while KeyBanc raised its target to $70 with an Overweight rating. The article also includes a promotional section on an "AI stock" with "10,000% upside potential."
Some Investors May Be Willing To Look Past Omnicell's (NASDAQ:OMCL) Soft Earnings
Omnicell's stock remained strong despite a recent soft earnings report, suggesting investors might be overlooking the immediate results. The company incurred a US$6.5 million expense due to unusual items, which, if non-recurring, could lead to higher profits next year. Analysts believe Omnicell's underlying earnings potential is better than it currently appears, despite a fall in earnings per share over the last year.
Omnicell's (NASDAQ:OMCL) Conservative Accounting Might Explain Soft Earnings
Omnicell, Inc. (NASDAQ:OMCL) recently reported soft earnings, but the market reacted positively. This article suggests that the seemingly low profits might be due to conservative accounting practices, specifically the impact of US$6.5m in unusual one-off expenses. If these unusual expenses do not recur, Omnicell's future profitability could be higher than current statutory numbers suggest, presenting a more optimistic outlook for investors.
3 Reasons to Avoid OMCL and 1 Stock to Buy Instead
This article recommends avoiding Omnicell (OMCL) despite its recent stock performance, citing three main reasons: mediocre long-term revenue growth, declining earnings per share (EPS), and an inability for previous growth initiatives to generate profitable returns. The author suggests that while Omnicell has seen recent market beating returns, it trades at a high forward P/E, indicating optimism that isn't supported by underlying fundamentals. Instead, the article advises investors to look for other opportunities with superior fundamentals.
Pharmacy Automation Systems Market to Get an Explosive Growth | McKesson Corporation, Omnicell Inc, Baxter International Inc
A new report by Coherent Market Insights projects explosive growth for the global Pharmacy Automation Systems Market between 2026 and 2033, driven by increasing demand and continuous innovation. The research provides in-depth analysis including market size, revenue performance, CAGR projections, competitive landscapes, and key player profiles such as McKesson Corporation and Omnicell Inc. It also covers market segmentation across various pharmacy types and geographical regions, offering strategic insights for industry leaders and investors.
Omnicell Names Former KU Health System Exec as Its Chief Pharmacy and Clinical Officer
Omnicell, a Fort Worth-based healthcare technology company focusing on autonomous medication management, has appointed Rick Couldry as senior vice president and chief pharmacy and clinical officer. In this new role, Couldry will leverage his 30 years of hospital pharmacy leadership experience to guide Omnicell’s innovation and portfolio strategies, ensuring solutions meet real-world clinical and operational needs. Previously, Couldry served as VP of pharmacy and health professions at The University of Kansas Health System, bringing extensive expertise in expanding specialty pharmacy services, leading operational transformations, and improving patient outcomes.
Here's why Omnicell (OMCL) is a strong momentum stock
This article from MSN discusses why Omnicell (OMCL) is considered a strong momentum stock. It likely details factors contributing to its upward trend and investor interest.
Omnicell (NASDAQ: OMCL) returns to profit with stronger Q1 2026 cash flow
Omnicell (NASDAQ: OMCL) reported a return to profitability in Q1 2026, posting a net income of $11.4 million compared to a net loss of $7.0 million in the prior year, driven by a 15% increase in total revenues to $309.9 million. The company also significantly improved its operating cash flow, which rose to $54.5 million from $25.9 million. Omnicell's financial flexibility is further enhanced by its undrawn $350 million revolving credit facility and the repayment of its 2025 convertible senior notes, leaving $172.5 million of 2029 notes outstanding.
Omnicell lifts 2026 non-GAAP EPS outlook to $1.80-$2.00 as Titan XT shipments are planned for 2H 2026
Omnicell, Inc. has raised its non-GAAP EPS outlook for 2026 to $1.80-$2.00, an increase from its previous forecast of $1.50-$1.75. This positive revision comes as the company announces plans to commence shipments of its new Titan XT product line in the second half of 2026. This improved outlook suggests potential growth and enhanced financial performance for Omnicell.
The 5 Most Interesting Analyst Questions From Omnicell’s Q1 Earnings Call
Omnicell (OMCL) exceeded Q1 Wall Street expectations with strong execution and operational improvements, driven by increased adoption of its connected devices, cost control, and a healthy order backlog. The company reconfirmed its revenue guidance and raised its Adjusted EPS and EBITDA guidance for the full year. Key analyst questions focused on retail pharmacy challenges, gross margin durability, adaptation to acute care changes, customer preferences for new platforms, and the use of financing options for large deals.
Omnicell (OMCL) Is Up 13.7% After Earnings Beat, Raised Guidance, And Key Pharmacy Hire - What's Changed
Omnicell (OMCL) saw a 13.7% increase in stock after reporting strong Q1 2026 earnings, raising full-year guidance, and hiring a new Senior Vice President, Chief Pharmacy and Clinical Officer. The company's focus on aligning automation and software with real-world pharmacy operations, coupled with improved profitability, suggests progress in its SaaS transition. While challenges like hospital budget pressures remain, these positive developments may shift investor confidence and analyst expectations for Omnicell's future growth and valuation.
North America Central Fill Pharmacy Automation Market Growth
The North America central fill pharmacy automation market is projected to grow from USD 427.0 million in 2026 to USD 822.8 million by 2033, exhibiting a compound annual growth rate (CAGR) of 11.4%. A new research study by Coherent Market Insights provides a comprehensive overview of the market, including competitive landscape analysis, segmentation by type and application, and key growth drivers and restraints. The report identifies top companies like Omnicell Inc., McKesson Corporation, and Parata Systems LLC, offering insights for strategic decision-making and investment planning.
Zacks Industry Outlook Highlights Veeva Systems, Doximity and Omnicell
The Medical Information Systems industry is growing due to rapid digitization and investment in data-driven healthcare, with innovations like machine learning and generative AI improving clinical decision support and workflow automation. Companies such as Veeva Systems, Doximity, and Omnicell are well-positioned for growth by offering digital health, cloud-enabled platforms, and AI-powered solutions, despite rising cybersecurity risks. Key trends include increased demand for remote healthcare, expanded AI applications in the medical sector, and an intensifying threat of cyberattacks.
Omnicell to Present at the BofA Securities 2026 Healthcare Conference
Omnicell, a leading healthcare technology provider focused on autonomous medication management, announced its presentation at the BofA Securities 2026 Healthcare Conference. The company will present on Tuesday, May 12, 2026, at 8:40 a.m. PDT. A live and archived webcast will be available on Omnicell's investor relations website.
Omnicell to Present at the BofA Securities 2026 Healthcare Conference
Omnicell, Inc. (Nasdaq:OMCL) announced it will present at the BofA Securities 2026 Healthcare Conference on Tuesday, May 12, 2026, at 8:40 a.m. PDT. A live and archived webcast of the presentation will be available on the company's investor relations website. Omnicell is a healthcare technology provider focused on autonomous medication management, aiming to improve efficiency and enhance patient safety.
Omnicell's May 12 healthcare conference presentation will stream live
Omnicell, Inc. (Nasdaq:OMCL) announced it will present at the BofA Securities 2026 Healthcare Conference on Tuesday, May 12, 2026, at 8:40 a.m. PDT. A live and archived webcast of the presentation will be available on the company's investor relations website. Omnicell specializes in healthcare technology focused on empowering autonomous medication management, aiming to improve efficiency and enhance patient safety.
Omnicell (OMCL) Is Up 13.7% After Earnings Beat, Raised Guidance, And Key Pharmacy Hire - What's Changed
Omnicell (OMCL) reported strong first-quarter 2026 results with an earnings beat and raised full-year guidance, along with the strategic hire of a new SVP, Chief Pharmacy and Clinical Officer. This positive performance, including a return to net income, is seen as a move to better align their automation and software with hospital pharmacy operations. The company's ability to maintain improved profitability will be key for investor confidence in its SaaS transition, though hospital budget pressures remain a risk.
Omnicell (OMCL) Is Up 13.7% After Earnings Beat, Raised Guidance, And Key Pharmacy Hire - What's Changed
Omnicell (OMCL) saw a 13.7% stock increase after reporting strong first-quarter 2026 earnings, including a revenue beat and return to positive net income, along with raising its full-year adjusted EPS guidance. The company also hired Rick Couldry as SVP, Chief Pharmacy and Clinical Officer, signaling a strategic move to align its product portfolio more closely with pharmacy operations. This performance suggests a potential shift in investor confidence regarding Omnicell's SaaS transition, despite ongoing concerns about hospital budgets and pricing pressures.
Omnicell (Nasdaq:OMCL) - Stock Analysis
This Simply Wall Street analysis provides an overview of Omnicell (OMCL), highlighting its valuation, future growth, past performance, and financial health. The company is currently trading 19.3% below its estimated fair value, with earnings projected to grow 36.22% annually. Recent news includes new product launches and analyst sentiment shifts regarding price targets and future earnings potential.
Discipline and Rules-Based Execution in OMCL Response
This article from Stock Traders Daily discusses a strong overweight bias for Omnicell Inc. (NASDAQ: OMCL) based on positive sentiment across all time horizons. It highlights an exceptional 62.4:1 risk-reward setup targeting a 17.7% gain, and outlines distinct institutional trading strategies for different risk profiles, including long, momentum breakout, and short hedging strategies. The analysis is supported by multi-timeframe signal analysis, indicating strong signals across near-term, mid-term, and long-term horizons.
Vanguard holds 2.27M shares in Omnicell (NASDAQ: OMCL)
Vanguard Capital Management has disclosed beneficial ownership of 2,274,766 shares of Omnicell (NASDAQ: OMCL) common stock, representing a 5% stake. This filing, a Schedule 13G, indicates a passive investment rather than an intent to influence the company. Vanguard holds sole dispositive power over all these shares and sole voting power over 340,249 shares.
Omnicell Reports Strong Q1 2026 Earnings, Raises Full-Year Guidance - News and Statistics
Omnicell reported strong first-quarter 2026 earnings, with revenue surging by almost 15% year-over-year to just under $310 million, surpassing analyst estimates. Non-GAAP net income more than doubled to $25 million, or $0.55 per share, significantly exceeding predictions. Following these results, the company raised its full-year 2026 revenue and adjusted net income per share guidance, causing its stock to jump nearly 21%.
Omnicell (OMCL) Q1 EPS Recovery Tests Bullish Margin Improvement Narrative
Omnicell (OMCL) began 2026 with a Q1 revenue of US$309.9 million and an EPS of US$0.25, with trailing twelve-month net margins remaining low at 1.7%. Despite bullish narratives around SaaS transition supporting better margins and stable earnings, historical data shows volatile profitability and a five-year earnings decline of 38.1% annually. The company's high P/E ratio of 95.9x suggests a premium valuation that requires significant future earnings growth to justify, which has not yet been confirmed by recent performance.
Vanguard (NASDAQ: OMCL) owns 3.24M Omnicell shares, 7.13% stake
Vanguard Portfolio Management has reported a beneficial ownership of 3,240,874 shares of Omnicell Inc. (NASDAQ: OMCL) common stock, which represents a 7.13% stake in the company as of March 31, 2026. This ownership was disclosed in a Schedule 13G filing, indicating a passive investment rather than an activist intent. Vanguard holds sole dispositive power over all 3.24 million shares but sole voting power over only 26,108 shares.
Omnicell Welcomes Hospital Pharmacy Leader Rick Couldry as Senior Vice President, Chief Pharmacy and Clinical Officer
Omnicell, Inc. has appointed Rick Couldry as Senior Vice President, Chief Pharmacy and Clinical Officer, a new role designed to integrate hospital pharmacy leadership perspectives into the company's innovation and portfolio decisions. Mr. Couldry brings 30 years of experience, emphasizing real-world clinical needs and enhanced patient outcomes in autonomous medication management. This strategic hire aims to strengthen Omnicell's solutions and commitment to improving patient care.
Omnicell Names Rick Couldry Chief Pharmacy and Clinical Officer
Omnicell, Inc. has appointed Rick Couldry as senior vice president and chief pharmacy and clinical officer, a new executive role. Couldry will serve as the company's senior clinical authority, guiding product strategy and strengthening ties with hospital pharmacy leaders. His extensive experience in hospital pharmacy leadership is expected to align Omnicell's medication management platforms with real-world clinical and operational demands.
KeyBanc raises Omnicell stock price target to $70 on growth outlook
KeyBanc has increased its price target for Omnicell Inc. (NASDAQ:OMCL) to $70 from $60, maintaining an Overweight rating, citing strong pipeline demand for its Titan XT cabinets and a confident outlook for a multi-year growth cycle. This revised target is based on a fiscal 2027 EV/Adj. EBITDA multiple of 20x, with the stock currently trading at $45.51, up 54% over the past six months. Omnicell recently reported robust Q1 2026 results, exceeding earnings and revenue expectations, further supporting the optimistic analyst views despite a potentially conservative fiscal 2026 bookings guidance.
Omnicell Names Rick Couldry Chief Pharmacy and Clinical Officer
Omnicell has appointed Rick Couldry as senior vice president and chief pharmacy and clinical officer, a newly created role where he will act as the company’s senior clinical authority. Couldry will integrate the perspective of health system pharmacy leaders into Omnicell's innovation and portfolio decisions, ensuring solutions align with real-world clinical and operational needs. His 30 years of hospital pharmacy leadership experience, including his previous role at The University of Kansas Health System, will be instrumental in advancing autonomous medication management.
Is It Too Late To Consider Omnicell (OMCL) After Its Recent 45% One Year Surge
Omnicell (OMCL) has seen a 45% surge over the past year, leading investors to question its current valuation. Simply Wall St's analysis suggests the stock is "ABOUT RIGHT" according to its Discounted Cash Flow model at $48.72 per share, indicating a small undervaluation compared to its current price of $45.51. However, using a Price vs. Sales ratio, the company appears "OVERVALUED" at 1.75x compared to a "Fair Ratio" of 1.04x, prompting a deeper look into valuation narratives.
A Look at Omnicell Inc (OMCL) After 20.9% Gain -- GF Value $38.04 vs Price $45.51
Omnicell Inc (OMCL) shares surged 20.9% to $45.51, which is 19.6% higher than its GF Value™ of $38.04, indicating it is overvalued. Despite an "Above Average" GF Score™ of 78/100, the stock shows concerning insider selling activity and a P/E ratio significantly above its historical median, suggesting caution for investors. Omnicell's Financial Strength and Profitability are stable, but its Growth rank is moderate.
Piper Sandler lowers Omnicell stock price target on lower estimates
Piper Sandler has lowered its price target for Omnicell Inc. (NASDAQ:OMCL) shares to $55 from $57, while maintaining an Overweight rating. This adjustment comes despite Omnicell exceeding first-quarter 2026 adjusted EBITDA and revenue guidance, and raising its full-year 2026 adjusted EBITDA and EPS guidance. The firm's decision to lower the price target is based on applying an unchanged 15x multiple to more conservative calendar year 2027 adjusted EBITDA estimates.
Piper Sandler raises Omnicell stock price target on earnings beat
Piper Sandler has increased its price target for Omnicell Inc. (NASDAQ:OMCL) to $57 from $49, maintaining an Overweight rating. This decision follows Omnicell's first-quarter fiscal 2026 adjusted EBITDA exceeding expectations by 42% and raising its full-year earnings guidance. The firm also noted strong services gross margin performance and expects net income to grow this year according to InvestingPro analysis.
